The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.

If you are wondering whether Merck's current share price still offers value, this article will walk through what the numbers are really saying about the stock. Merck closed at US$115.61, with returns ...

Merck & Co., Inc. (NYSE:MRK) has been on a strong recovery run, gaining 23% over the past year and 8% year-to-date, though ...

A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, Keytruda. The drug contributes over half of the company’s pharmaceutical ...

In late February 2026, Merck reported a wave of positive late-stage data and regulatory milestones for KEYTRUDA-based ...

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

In recent weeks, Merck secured new regulatory milestones for its KEYTRUDA franchise, including U.S. FDA approval for KEYTRUDA ...

Merck MRK announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab). This version, which will be marketed as ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...